[HTML][HTML] Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model
DA van den Born, AG Märtson, A Veringa… - International journal of …, 2023 - Elsevier
Background Voriconazole is an antifungal drug used for the treatment of invasive fungal
infections. Due to highly variable drug exposure, therapeutic drug monitoring (TDM) has …
infections. Due to highly variable drug exposure, therapeutic drug monitoring (TDM) has …
Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens
L Purkins, N Wood, P Ghahramani… - Antimicrobial agents …, 2002 - Am Soc Microbiol
In this study, the safety, tolerability, and pharmacokinetics of intravenous (iv)-to oral-dose
regimens of voriconazole were evaluated with a group of 42 healthy men, 41 of whom …
regimens of voriconazole were evaluated with a group of 42 healthy men, 41 of whom …
Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole
L Purkins, N Wood, D Kleinermans… - British Journal of …, 2003 - Wiley Online Library
Aims Voriconazole, a new triazole antifungal agent, is metabolized mainly by cytochrome
P450s CYP2C19 and CYP2C9, and also by CYP3A4. The aim of this open‐label, placebo …
P450s CYP2C19 and CYP2C9, and also by CYP3A4. The aim of this open‐label, placebo …
Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole
B Moriyama, S Kadri, SA Henning, RL Danner… - Current fungal infection …, 2015 - Springer
Voriconazole is an antifungal triazole that is the first-line agent for treatment of invasive
aspergillosis. It is metabolized by CYP2C19, CYP2C9, and CYP3A4 and demonstrates wide …
aspergillosis. It is metabolized by CYP2C19, CYP2C9, and CYP3A4 and demonstrates wide …
Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections
KM Job, J Olson, C Stockmann… - Expert review of anti …, 2016 - Taylor & Francis
Introduction: Voriconazole is a broad-spectrum antifungal agent commonly used to treat
invasive fungal infections (IFI), including aspergillosis, candidiasis, Scedosporium infection …
invasive fungal infections (IFI), including aspergillosis, candidiasis, Scedosporium infection …
Voriconazole
LA Jeu, FJ Piacenti, AG Lyakhovetskiy, HB Fung - Clinical therapeutics, 2003 - Elsevier
Background: Reports of resistance and intolerance to currently available antifungal agents
are increasing. Voriconazole is a broad-spectrum azole antifungal agent structurally derived …
are increasing. Voriconazole is a broad-spectrum azole antifungal agent structurally derived …
Clinical pharmacokinetics of voriconazole
D Levêque, Y Nivoix, F Jehl, R Herbrecht - International journal of …, 2006 - Elsevier
Clinical pharmacokinetics of voriconazole - ScienceDirect Skip to main contentSkip to article
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue Search …
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue Search …
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections
T Wang, H Zhu, J Sun, X Cheng, J Xie, H Dong… - International journal of …, 2014 - Elsevier
The aim of this study was to determine an optimum voriconazole target concentration, to
study the influence of CYP2C19 gene status on metabolism of voriconazole and to identify a …
study the influence of CYP2C19 gene status on metabolism of voriconazole and to identify a …
Influence of inflammation on voriconazole metabolism
MA Encalada Ventura, LFR Span… - Antimicrobial Agents …, 2015 - Am Soc Microbiol
Voriconazole pharmacokinetics shows a large inter-and intrapatient variability. Inflammation
is associated with changes in the expression of CYP isoenzymes. Here, we evaluated the …
is associated with changes in the expression of CYP isoenzymes. Here, we evaluated the …
Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics
N Hohmann, R Kreuter, A Blank, J Weiss… - British Journal of …, 2017 - Wiley Online Library
Aims The pharmacokinetics of voriconazole show a nonlinear dose–exposure relationship
caused by inhibition of its own CYP3A‐dependent metabolism. Because the magnitude of …
caused by inhibition of its own CYP3A‐dependent metabolism. Because the magnitude of …